Sugi Predict

Sugi Predict / Compounds / SCHEMBL6486381

SCHEMBL6486381

SCHEMBL6486381

N[C@H](CC1CCCCC1)C(O)C(=O)NN(CCCC(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 15/20 0.56
▸ METAP1 P53582 8/20 0.56
▸ MMP1 P03956 1/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ PSEN1 P49768 2/20 0.37
▸ PSEN2 P49810 2/20 0.37
▸ APH1B Q8WW43 2/20 0.37
▸ NCSTN Q92542 2/20 0.37
▸ APH1A Q96BI3 2/20 0.37
▸ PSENEN Q9NZ42 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489285 0.90 METAP2 (0.56) METAP2METAP1MMP1MMP2MMP3
SCHEMBL6478108 0.89 METAP2 (0.55) METAP2METAP1ATM
SCHEMBL6488177 0.89 METAP2 (0.55) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6486453 0.88 METAP2 (0.57) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6477530 0.88 METAP2 (0.57) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6488054 0.88 METAP2 (0.57) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6486492 0.88 METAP2 (0.57) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6482969 0.88 METAP2 (0.57) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6478450 0.87 METAP2 (0.58) METAP2METAP1ATMPSEN1PSEN2
SCHEMBL6484050 0.87 METAP2 (0.53) METAP2METAP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 — — US claimed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 — — EP claimed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 — — US claimed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 — — US claimed
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 — — US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 — — EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 — — US disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP METAP2 1/4885METAP1 2/4885MMP1 40/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP METAP2 1/4885METAP1 2/4885MMP1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.